RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Insider activity. I agree and it is obvious that there is always the danger of another treatment or technology leap frogging over other companies. In a partner situation financing would be an issue not with abuyout as the BP becomes the financier. But, it does beg the question....Is BP trying to starve Oncy into submission. The ethical choice is to move a promising drug along but money gets in the way most of the time.
As far as new treaments coming along. Could it be as simple as this.
In the study, 34 patients with stage 4 metastatic pancreatic cancer were randomized to receive either standard chemotherapy (gemcitabine and nab-paclitaxel), or the chemotherapy plus infusions of high-dose vitamin C. The results showed that average overall survival was 16 months for the patients receiving the chemotherapy plus vitamin C, compared to eight months for the patients getting just chemotherapy. In addition, progression free survival was extended from four months to six months.
“Not only does it increase overall survival, but the patients seem to feel better with the treatment," Cullen says. “They have less side effects, and appear to be able to tolerate more treatment, and we've seen that in other trials, too.”
The new study is not the only evidence of the benefit of including IV vitamin C as part of cancer treatment. Earlier this year, the results of another UI phase 2 clinical trial in patients with glioblastoma, a deadly form of brain cancer, were published. That study also showed a significant increase in survival when high-dose, IV vitamin C was added to standard of care chemotherapy and radiation. Cullen was also part of that trial along with his colleague Bryan Allen, MD, PhD, UI professor and head of radiation oncology.